

Mucositis

[View the current Mucositis InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Mucositis.html>) - Regularly Updated.

Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. Oral and gastrointestinal mucositis can affect up to 100% of patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation, 80% of patients with malignancies of the head and neck receiving radiotherapy, and a wide range of patients receiving chemotherapy. Alimentary track mucositis increases mortality and morbidity and contributes to rising health care costs. For most cancer treatment, about 5-15% of patients get mucositis. However, with 5-fluorouracil, up to 40% get mucocitis, and 10-15% get grade 3-4 oral mucositis. Irinotecan is associated with severe GI mucositis in over 20% of patients. 75-85% of bone marrow transplantation recipients experience mucositis, of which oral mucositis is the most common and most debilitating, especially when melphalan is used. In grade 3 oral mucositis, the patient is unable to eat solid food, and in grade 4, the patient is unable to consume liquids as well. Rubenstein Radiotherapy to the head and neck or to the pelvis or abdomen is associated with Grade 3 and Grade 4 oral or GI mucositis, respectively, often exceeding 50% of patients. Among patients undergoing head and neck radiotherapy, pain and decreased oral function may persist long after the conclusion of therapy. Fractionated radiation dosage increases the risk of mucositis to > 70% of patients in most trials. Oral mucositis is particularly profound and prolonged among HSCT recipients who receive total-body irradiation. Rubenstein ([From the Wikipedia article Mucositis](#).)

Recent Publications on Mucositis:



- [The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review.](#)
Although pelvic radiotherapy, either alone or combined with chemotherapy,... 21st November, 2009
Radiotherapy Department, Attikon University Hospital, Medical School of- Recent Pat Inflamm Allergy Drug Discov. 2009 Nov;3(3):195-200.
- [Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.](#)
Genetic variations of the enzymes involved in chemotherapy metabolism in... 20th November, 2009
aPediatric Department, Faculty of Medicine, Ain Shams University, Egypt- Blood Coagul Fibrinolysis. 2009 Nov 17. ([DOI Direct Link](#))
- [Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study.](#)
PURPOSE: Ixabepilone (BMS-247550) is a microtubule-stabilizing epothilone... 18th November, 2009
University of Iowa Hospitals and Clinics, Iowa City, IA; Gynecologic- J Clin Oncol. 2009 Nov 16. ([DOI Direct Link](#))
- [Effectiveness of a Home Care Nursing Program in the Symptom Management of Patients With](#)

[Colorectal and Breast Cancer Receiving Oral Chemotherapy: A Randomized, Controlled Trial.](#)

*PURPOSE: To assess the effectiveness of a symptom-focused home care...*18th November, 2009
School of Nursing, Midwifery, and Social Work, University of Manchester;- J Clin Oncol. 2009 Nov 16. ([DOI Direct Link](#))

• [Triple MEL100 Therapy in Multiple Myeloma.](#)

*BACKGROUND: Tandem high-dose melphalan therapy with autologous peripheral...*18th November, 2009
Brown University, Providence, Rhode Island, United States.- Transplant Proc. 2009 Nov;41(9):3863-7. ([DOI Direct Link](#))

• [Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life.](#)

*GOALS OF WORK: This study determined the incidence of severe oral...*17th November, 2009
Faculty of Medicine, The Nethersole School of Nursing, The Chinese- Support Care Cancer. 2009 Nov 15. ([DOI Direct Link](#))

• [Comparison of the effects of treatment of peri-implant infection in animal and human studies: systematic review and meta-analysis.](#)

*Abstract Objective: The main objective of this systematic review is to...*17th November, 2009
Department of Prosthodontics, Division of Periodontics, School of- Clin Oral Implants Res. 2009 Nov 13. ([DOI Direct Link](#))

• [A Diet Containing Whey Protein, Glutamine, and TGFbeta Modulates Gut Protein Metabolism During Chemotherapy-Induced Mucositis in Rats.](#)

*BACKGROUND: Mucositis, a common side effect of chemotherapy, is...*17th November, 2009
ADEN EA4311 Institute for Biomedical Research and European Institute for- Dig Dis Sci. 2009 Nov 13. ([DOI Direct Link](#))

• [Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation.](#)

*Purpose. Oral mucositis is a serious problem that affects a significant...*17th November, 2009
Memorial Sloan Kettering Cancer Center (Mayo Clinic Florida at the time of- J Oncol Pharm Pract. 2009 Nov 12. ([DOI Direct Link](#))

• [Fotemustine plus etoposide, cytarabine and melphalan \(FEAM\) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.](#)

*BEAM is a widely used conditioning regimen for relapsed/refractory...*10th November, 2009
Department of Oncology, Oncohematology and Bone Marrow Transplantation- Bone Marrow Transplant. 2009 Nov 9. ([DOI Direct Link](#))

• [Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy.](#)

*Background and Objective: Intensity-modulated radiotherapy (IMRT) has...*10th November, 2009
Department of Radiation Oncology, Teaching Hospital of Fujian Medical- Chin J Cancer. 2009 Nov 5;28(11):1143-8.

• [Perioral abscess associated with isotretinoin.](#)

*Severe scarring acne is frequently treated with isotretinoin. Patients...*10th November, 2009
University of Miami, Department of Dermatology, Miami, FL, USA.- J Drugs Dermatol. 2009 Nov;8(11):1034-6.

• [Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.](#)

*BACKGROUND: Panitumumab has the potential to improve the therapeutic ratio...*7th November, 2009
Division of Hematology-Oncology, Department of Medicine, Massachusetts- Ann Oncol. 2009 Nov 5. ([DOI Direct Link](#))

• [The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review.](#)

*Although pelvic radiotherapy, either alone or combined with chemotherapy,...*7th November, 2009
Radiotherapy Department, Attikon University Hospital, Medical School of- Recent Pat Inflamm Allergy Drug Discov. 2009 Nov 1.

• [Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer](#)

[patients: A Multicenter Phase II Trial.](#)

OBJECTIVE: To evaluate the efficacy of pegylated liposomal doxorubicin...6th November, 2009
Centre Francois Baclesse, 3 avenue du General Harris, 14076 CAEN cedex 05,- Gynecol Oncol. 2009
Nov 2. ([DOI Direct Link](#))

BioNews Results for Mucositis

- [Findings on the use of Traumeel S in children with mucositis undergoing SCT presented](#)
News-Medical.Net: Nov 13 2009 11:48AM Matching: mucositis
- [Access Pharmaceuticals recent pull back could be a buying opportunity](#)
Proactive Investors.co.uk: Nov 12 2009 12:54PM Matching: mucositis
- [Allos Therapeutics Announces New Data on FOLOTYN to be Presented at the American Society of Hematology Meeting](#)
Yahoo! Canada: Nov 11 2009 3:11PM Matching: mucositis
- [Mucositis: The impact, biology and therapeutic opportunities of oral mucositis](#)
MDLinx: Oct 21 2009 1:06PM Matching: mucositis

Mucositis Patents:



- 7514458- [Anti-cytokine heterocyclic compounds](#)
- 7541434- [Polypeptide for a TRP channel family member, TRP-PLIK2, and splice variants](#)
- 7544348- [Liquid formulations for the prevention and treatment of mucosal diseases and disorders](#)
- 7547433- [Liquid formulations for the prevention and treatment of mucosal diseases and disorders](#)
- 7550461- [Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases](#)
- 7550501- [Compounds and methods for treating toll-like receptor 2-related diseases and conditions](#)
- 7553850- [Tricyclic-bridged piperidinyldene derivatives as .delta.-opioid modulators](#)
- 7563770- [Glucagon-like-peptide-2 \(GLP-2\) analogues](#)
- 7563810- [Methods of using 3-\(4-amino-1-oxo-1,3-dihydroisoindol-2-yl\)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases](#)
- 7563899- [\(S\)-N-methylnaltrexone](#)
- 7566740- [Method of treating mucositis](#)
- 7538082- [Methods and compositions for treating oral and esophageal lesions](#)
- 7534455- [Herbal composition PHY906 and its use in chemotherapy](#)
- 7521424- [Albumin fusion proteins](#)
- 7521542- [Humanized Fc.gamma.RIIB-specific antibodies and methods of use thereof](#)
- 7522955- [Method and apparatus for the ultrasonic cleaning of biofilm coated surfaces](#)
- 7524814- [Lactoferrin compositions and methods of wound treatment](#)
- 7527642- [Hinged therapeutic mouthpiece](#)
- 7528105- [Heterodimeric chain synthetic heparin-binding growth factor analogs](#)
- 7528236- [Humanized anti-beta7 antagonists and uses therefor](#)
- 7531310- [Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11](#)

- 7531560- [Anti-cytokine heterocyclic compounds](#)
- 7531562- [Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy](#)
- 7569364- [Anti-NGF antibodies and methods using same](#)
- 7569384- [Albumin fusion proteins](#)
- 7569568- [Cytokine inhibitors](#)
- 7595341- [Analogues of lipid mediators derived from .omega.-3 PUFAs and methods of use](#)
- 7598224- [Dual chain synthetic heparin-binding growth factor analogs](#)
- 7598260- [CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7601359- [Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins](#)
- 7601719- [Compounds, methods and pharmaceutical compositions for inhibiting PARP](#)
- 7601800- [Compositions and methods for monitoring breast cancer treatment](#)
- 7604799- [EphA4 Antibodies](#)
- 7605143- [2-propynyl adenosine analogs with modified 5'-ribose groups having A.sub.2A agonist activity](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)
- 7595039- [Methods of healing wounds by administering human IL-18](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7572456- [Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof](#)
- 7576069- [2-polycyclic propynyl adenosine analogs having A2A agonist activity](#)
- 7582650- [Tricyclic opioid modulators](#)
- 7589076- [Substituted aryl piperidinylalkynyladenosines as A2AR agonists](#)
- 7589103- [Tricyclic-bridged piperidinylidene derivatives as 8-opioid modulators](#)
- 7589104- [Tricyclic-bridged piperidinylidene derivatives as .sctn.-opioid modulators](#)
- 7591997- [Method for determining the susceptibility of a subject to infection](#)
- 7592010- [Albumin fusion proteins](#)
- 7592332- [Cytokine inhibitors](#)
- 7592342- [Quinoxaline derivatives as PI3 kinase inhibitors](#)
- 7612071- [Compositions and methods employing aminopterin](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

